BioSpace News Archive

The Montreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models

BIOMODEX®, a pioneering digital health company that offers unique and enhanced 3D printed solutions for patient-specific rehearsal and physician training, today announced the appointment of Bill Perusek as Vice President of U.S. Sales.

Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board, at its meeting today, approved the appointment of Hedi Ben Brahim as the Company’s new Chairman and CEO, effective January 1 st , 2021. Hedi Ben Brahim, who has been a member of Transgene’s Board since May 2019, will replace Philippe Archinard. Philippe Archi

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Abivax (Euronext Paris:FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar. Thursday, April 1, 2021 Publication of financial statements as of December 31, 2020 Friday, April 30, 2021 Publication and release of the 2020 annual financial report Friday, June 4, 2021

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of TG4001, a HPV16 targeted therapeutic vaccine, in combination with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies at ESMO Immuno-Oncology Virtual Congress 2020, December 9-12, 2020.

Tauriga Sciences, Inc., a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums as well as two ongoing Biotechnology initiatives, confirmed the retirement of its previously outstanding $88,333.00 Face Value 8.00% Convertible Debenture, issued to a New York City based Institutional Investor on May 18, 2020.

BioAesthetics Corporation today announced a clinical study of its nipple reconstruction graft will be performed at Stanford Medicine beginning in 2021. The BioAesthetics® NACgraft™ biologic matrix is a decellularized skin allograft of the human nipple-areolar complex (NAC) intended to replace the NAC when lost due to mastectomy or other procedure

Therap is announcing the release of its interface to Sandata, DHCF’s mandated EVV data aggregator.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that the Company successfully demonstrated its Nanox.ARC next-generation x-ray prototype at the 2020 Radiology Society of North America (RSNA) Virtual Annual Meeting